From the American Academy of Ophthalmology

This analysis of data from the Comparison of AMD Treatments Trial (CATT) shows that scar developed in 45.3 percent by the end of the two-year trial, with 339 of the 480 eyes developing a scar during the first year of treatment. Those more likely to develop a scar had classic choroidal neovascularization, blocked fluorescence on fluorescein angiography, increased retinal thickness, and more fluid or material under the foveal center of the retina. Fibrotic scars developed in 24.7 percent and nonfibrotic scars developed in 20.6 percent. Drug choice, dosing regimen, and genotyping had no impact on scar risk. Ophthalmology, March 2014